Hepatocellular carcinoma
Conditions
Interventions
Transcatheter arterial chemolipiodolization with miriplatin
Transcatheter arterial infusion with lipiodol
Sponsors
Second department of surgery, Dokkyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age over 20 years old. 2) Written informed consent 3) The tumor number <= 3 nodules in the liver. The maximum tumor diameter without limit. 4) Adequate organ function for 2 weeks before transcatheter arterial infusion.
Exclusion criteria
Exclusion criteria: 1) Patients who have medical history of hypersensitivity of platinum-containing drug, iodine-containing drug and gelatine. 2) Patients with serious complications(Severe thyroid disease, Severe heart disease and the like.) 3) Patients with active double cancer. 4) Patients with bile duct invasion. 5) Pregnant and lactating females; males and females of childbearing age unless using effective contraception. 6) Patients without remarkable findings of A-V shunt and/or A-P shunt. 7) Tumor thrombosis in main portal vein or vena cava 8) Patients who are concluded to be inappropriate to participate in this study by their physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recurrence rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to recurrence Tumor marker assessment | — |
Countries
Japan
Contacts
Public ContactMasato Kato
Dokkyo Medical University Second department of surgery
Outcome results
None listed